BREAST CANCER

>

Latest News

Neoadjuvant Pembrolizumab With Chemotherapy Boosts OS in Early TNBC
Neoadjuvant Pembrolizumab With Chemotherapy Boosts OS in Early TNBC

May 28th 2024

Pembrolizumab combined with chemotherapy significantly improved overall survival in patients with high-risk early triple-negative breast cancer, according to the prespecified interim analysis of the phase 3 KEYNOTE-522 trial.

Inavolisib Regimen Wins FDA Breakthrough Therapy Designation for PIK3CA+ Breast Cancer
Inavolisib Regimen Wins FDA Breakthrough Therapy Designation for PIK3CA+ Breast Cancer

May 21st 2024

Sequencing Sacituzumab and Other Drugs in HR+, HER2- Breast Cancer
Sequencing Sacituzumab and Other Drugs in HR+, HER2- Breast Cancer

May 16th 2024

Palazestrant With Ribociclib Shows Promising Early Results in ER+/HER2- mBC
Palazestrant With Ribociclib Shows Promising Early Results in ER+/HER2- mBC

May 16th 2024

FDA Clears IND of BTX-9341 in HR+/HER2- Breast Cancer
FDA Clears IND of BTX-9341 in HR+/HER2- Breast Cancer

May 7th 2024

Latest CME Events & Activities

Clinical Case Vignette Series™: 40th Annual Miami Breast Cancer Conference®

View More

Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician

View More

HER2+ Breast Cancer Tumor Board: Navigating Current and Evolving Strategies from Early Stages to Metastases

View More

Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure

View More

Show Me the Data®: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

23rd Annual International Congress on the Future of Breast Cancer® West

July 12-13, 2024

Register Now!

23rd Annual International Congress on the Future of Breast Cancer® East

July 19-20, 2024

Register Now!

Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer

View More

Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed

View More

Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease

View More

Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer

View More

Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care

View More

Community Practice Connections®: Evaluating the Evolving Treatment Landscape for mHR+ Breast Cancer-How to Personalize Care and Improve Patient Outcomes

View More

Community Practice Connections™: Leveraging Multidisciplinary Teams in Early-Stage Breast Cancer When the Goal Is Cure

View More

Community Practice Connections™: 22nd Annual International Congress on the Future of Breast Cancer®

View More

6th Annual Precision Medicine Symposium: An Illustrated Tumor Board

October 18-19, 2024

Register Now!

Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes

View More

22nd Annual School of Breast Oncology

November 7-9, 2024

Register Now!

42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®

November 13-15, 2024

Register Now!

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer

View More

Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs

View More

Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings

View More

Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs

View More

School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio

View More

41st Annual CFS®: Innovative Cancer Therapy for Tomorrow

View More

42nd Annual Miami Breast Cancer Conference®

March 6 - 9, 2025

Register Now!

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

View More

Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice

View More

More News